Literature DB >> 3159807

Leprosy: altered complement receptors in disseminated disease.

F Tausk, T Hoffmann, R Schreiber, I Gigli.   

Abstract

We have studied the expression of the C3b receptor (CR1) on erythrocytes of 55 patients with Hansen's disease. We developed a radioimmunoassay utilizing a monoclonal antibody that recognized an epitope different from the C3b binding site, which therefore enabled us to measure total number of CR1 regardless of receptor occupancy. We observed that patients in the lepromatous pole of the disease had a mean of 310 CR1/erythrocyte, whereas the ones in the tuberculoid pole showed a mean of 577 CR1/erythrocyte; 77 normal controls had a mean of 512 CR1/erythrocyte. The number of C3b receptors on the cells of lepromatous patients was significantly decreased (p less than .001) when compared to the normal population or tuberculoid patients. The presence of receptors for the C3b fragment of complement (CR1) on the surface of human erythrocytes enables these cells to participate in a number of immune functions including the clearance of circulating immune complexes. These findings could bear importance in the ability of the host to clear immune complexes from the circulation in patients with lepromatous leprosy.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3159807     DOI: 10.1111/1523-1747.ep12275477

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  2 in total

1.  Altered erythrocyte C3b receptor expression, immune complexes, and complement activation in homosexual men in varying risk groups for acquired immune deficiency syndrome.

Authors:  F A Tausk; A McCutchan; P Spechko; R D Schreiber; I Gigli
Journal:  J Clin Invest       Date:  1986-10       Impact factor: 14.808

2.  Human complement receptor type 1 (CR1) protein levels and genetic variants in chronic Chagas Disease.

Authors:  Thaisa Lucas Sandri; Kárita Cláudia Freitas Lidani; Fabiana Antunes Andrade; Christian G Meyer; Peter G Kremsner; Iara J de Messias-Reason; Thirumalaisamy P Velavan
Journal:  Sci Rep       Date:  2018-01-11       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.